The DOI matches its Crossref record.
P02-06: Effect of systemic treatment on telomere length of patients with metastatic colorectal cancer
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In colorectal cancer patients, peripheral blood lymphocytes contain shorter telomeres than those of healthy individuals.
“This is important because it is proven that in CRC patients, peripheral blood lymphocytes (PBLs) contain shorter telomeres than those of healthy individuals [29]”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [29]
In a recent study, Nikolouzakis et al. showed that telomere length in peripheral blood leukocytes from patients with mCRC tends to decrease with age (especially for patients over 75 years old) when compared to healthy individuals of the same age, while chemotherapy seemed to also have a negative impact on the mean telomere length of mCRC patients.
“In a recent study, Nikolouzakis et al. showed that TL in PBLs from patients with mCRC tends to decrease with age (especially for patients over 75 years old) when compared to healthy individuals of the same age, while chemotherapy seemed to also have a negative impact on the mean TL of mCRC patients [29].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [29]
Telomere length has emerged as a potential predictive biomarker for the clinical outcome of anti-EGFR monoclonal antibody therapy in patients with KRAS wild-type metastatic CRC.
“Furthermore, TL has emerged as a potential predictive biomarker for the clinical outcome of anti-EGFR monoclonal antibody therapy in patients with KRAS wild-type metastatic CRC.”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [29]
Citations
Cited by
Sorted by citations
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
Self-citation
Metadata
- Authors
- Nikolouzakis, T. K., Vakonaki, E., Alegakis, A., Rakitskii, V., Svistunov, A., Chrysos, E., Souglakos, J., Tsatsakis, A. M., & Tsiaoussis, J.
- Affiliations
- University of Crete (GR)
- Sechenov University (RU)
- University Hospital of Heraklion (GR)
- Venue
- Toxicology Letters
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 384
- Pages
- S83
- ISSN
- 0378-4274 (ISSN-L)
- OpenAlex
- W4386481766
- Cited by
- 1
- References
- 0
- Citations by year
- 2024: 1
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Toxicology Letters (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- telomere length, metastatic colorectal cancer, systemic chemotherapy, chemotherapy toxicity, telomere shortening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
